GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Debt-to-EBITDA

Tourmaline Bio (Tourmaline Bio) Debt-to-EBITDA : -0.02 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tourmaline Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.22 Mil. Tourmaline Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.19 Mil. Tourmaline Bio's annualized EBITDA for the quarter that ended in Dec. 2023 was $-25.27 Mil. Tourmaline Bio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Tourmaline Bio's Debt-to-EBITDA or its related term are showing as below:

TRML' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.03   Med: -0.02   Max: -0.01
Current: -0.03

During the past 3 years, the highest Debt-to-EBITDA Ratio of Tourmaline Bio was -0.01. The lowest was -0.03. And the median was -0.02.

TRML's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs TRML: -0.03

Tourmaline Bio Debt-to-EBITDA Historical Data

The historical data trend for Tourmaline Bio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Debt-to-EBITDA Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
N/A -0.03 -0.01

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial - - N/A -0.02 -0.02

Competitive Comparison of Tourmaline Bio's Debt-to-EBITDA

For the Biotechnology subindustry, Tourmaline Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's Debt-to-EBITDA falls into.


Tourmaline Bio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tourmaline Bio's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.221 + 0.194) / -45.376
=-0.01

Tourmaline Bio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.221 + 0.194) / -25.268
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Tourmaline Bio  (NAS:TRML) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Tourmaline Bio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Debt-to-EBITDA
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.